Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.52 |
| ▸ | MTOR | P42345 | 7/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123709 | 0.82 | LMNA (0.51) | PIK3CAMTORUSP2ALOX15HSD17B10 | |
| SCHEMBL1123934 | 0.82 | LMNA (0.51) | PIK3CAMTORUSP2ALOX15HSD17B10 | |
| SCHEMBL1123846 | 0.81 | KDM4E (0.42) | PIK3CAMTORTLR9HSD17B10LMNA | |
| SCHEMBL1123915 | 0.80 | HRH4 (0.50) | PIK3CALMNAKDM4EALDH1A1 | |
| SCHEMBL1124043 | 0.80 | HRH4 (0.50) | PIK3CALMNAKDM4EALDH1A1 | |
| SCHEMBL1123815 | 0.80 | HRH4 (0.50) | PIK3CALMNAKDM4EALDH1A1 | |
| SCHEMBL1124138 | 0.79 | PIK3CA (0.49) | PIK3CAMTORTLR9LMNAKDM4E | |
| SCHEMBL12563010 | 0.78 | ALDH1A1 (0.51) | LMNAKDM4EALDH1A1 | |
| SCHEMBL1123937 | 0.77 | DRD2 (0.46) | PIK3CAMTOR | |
| SCHEMBL1123740 | 0.76 | ADRB1 (0.54) | PIK3CALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | claimed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | claimed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | CASP3, DPYD, CASP1 | PIK3CA 2922/4885MTOR 1611/4885TLR9 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.